LT3580220T - Aminotriazolopiridinai, kaip kinazės inhibitoriai - Google Patents

Aminotriazolopiridinai, kaip kinazės inhibitoriai

Info

Publication number
LT3580220T
LT3580220T LTEPPCT/US2018/017755T LT18017755T LT3580220T LT 3580220 T LT3580220 T LT 3580220T LT 18017755 T LT18017755 T LT 18017755T LT 3580220 T LT3580220 T LT 3580220T
Authority
LT
Lithuania
Prior art keywords
aminotriazolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
LTEPPCT/US2018/017755T
Other languages
English (en)
Inventor
Junqing Guo
Amy Hart
John Macor
Michael Mertzman
William Pitts
Steven Spergel
Scott Watterson
Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Jie Chen
Carolyn Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3580220T publication Critical patent/LT3580220T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/US2018/017755T 2017-02-13 2018-02-12 Aminotriazolopiridinai, kaip kinazės inhibitoriai LT3580220T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
LT3580220T true LT3580220T (lt) 2021-12-27

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/017755T LT3580220T (lt) 2017-02-13 2018-02-12 Aminotriazolopiridinai, kaip kinazės inhibitoriai

Country Status (25)

Country Link
US (3) US10913738B2 (lt)
EP (1) EP3580220B1 (lt)
JP (1) JP7097373B2 (lt)
KR (1) KR102549952B1 (lt)
CN (1) CN110520423B (lt)
AU (1) AU2018217488B2 (lt)
BR (1) BR112019016635A2 (lt)
CA (1) CA3053484A1 (lt)
CY (1) CY1124978T1 (lt)
DK (1) DK3580220T3 (lt)
EA (1) EA039808B1 (lt)
ES (1) ES2902676T3 (lt)
HR (1) HRP20212000T1 (lt)
HU (1) HUE057801T2 (lt)
IL (1) IL268614B (lt)
LT (1) LT3580220T (lt)
MA (1) MA47460A (lt)
MX (1) MX378515B (lt)
PL (1) PL3580220T3 (lt)
PT (1) PT3580220T (lt)
RS (1) RS62801B1 (lt)
SG (1) SG11201907335UA (lt)
SI (1) SI3580220T1 (lt)
SM (1) SMT202200001T1 (lt)
WO (1) WO2018148626A1 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2902676T3 (es) * 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
ES2905948T3 (es) * 2017-10-30 2022-04-12 Bristol Myers Squibb Co Aminoimidazopiridazinas como inhibidores de cinasa
BR112020014516A2 (pt) 2018-01-26 2020-12-08 Bristol-Myers Squibb Company Aminopirrolotriazinas como inibidores de quinase
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
US12172975B2 (en) 2018-09-13 2024-12-24 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
TWI724753B (zh) * 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
AU2020246313B2 (en) * 2019-03-22 2022-08-04 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
IL291828A (en) 2019-10-03 2022-06-01 Bristol Myers Squibb Co Inazole Carboximides as Kinase Inhibitors
CN115135648B (zh) * 2020-02-13 2024-02-09 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物,其制法与医药上的用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
EP4495119A4 (en) 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
AR133939A1 (es) * 2023-09-27 2025-11-19 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de cinasa
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
SG186040A1 (en) 2007-11-27 2012-12-28 Cellzome Ltd Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
CA2750517A1 (en) 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
HK1219737A1 (zh) 2013-06-10 2017-04-13 Bayer Pharma Aktiengesellschaft 用於治疗癌症的新化合物
AU2015304851A1 (en) * 2014-08-21 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as RIP1 kinase inhibitors as medicaments
CN108349970B (zh) 2015-11-05 2021-03-05 住友化学株式会社 稠合杂环化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
EP3575298B1 (en) 2017-01-24 2022-03-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
ES2902676T3 (es) * 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
ES2905948T3 (es) 2017-10-30 2022-04-12 Bristol Myers Squibb Co Aminoimidazopiridazinas como inhibidores de cinasa
BR112020014516A2 (pt) 2018-01-26 2020-12-08 Bristol-Myers Squibb Company Aminopirrolotriazinas como inibidores de quinase
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
JP2020507582A (ja) 2020-03-12
MA47460A (fr) 2019-12-18
DK3580220T3 (da) 2022-01-10
CY1124978T1 (el) 2023-01-05
EA201991915A1 (ru) 2019-12-30
KR102549952B1 (ko) 2023-06-29
ES2902676T3 (es) 2022-03-29
SG11201907335UA (en) 2019-09-27
CN110520423A (zh) 2019-11-29
MX2019009555A (es) 2019-10-02
US10913738B2 (en) 2021-02-09
EA039808B1 (ru) 2022-03-16
RS62801B1 (sr) 2022-02-28
AU2018217488A1 (en) 2019-10-03
HUE057801T2 (hu) 2022-06-28
US20250074909A1 (en) 2025-03-06
AU2018217488B2 (en) 2021-09-23
CN110520423B (zh) 2022-08-23
HRP20212000T1 (hr) 2022-04-01
MX378515B (es) 2025-03-11
CA3053484A1 (en) 2018-08-16
US20220315580A1 (en) 2022-10-06
IL268614A (en) 2019-10-31
SI3580220T1 (sl) 2022-01-31
WO2018148626A1 (en) 2018-08-16
SMT202200001T1 (it) 2022-03-21
US12157733B2 (en) 2024-12-03
EP3580220B1 (en) 2021-11-17
US20190389859A1 (en) 2019-12-26
JP7097373B2 (ja) 2022-07-07
BR112019016635A2 (pt) 2020-04-07
IL268614B (en) 2021-12-01
EP3580220A1 (en) 2019-12-18
KR20190117006A (ko) 2019-10-15
PL3580220T3 (pl) 2022-02-07
PT3580220T (pt) 2022-01-03

Similar Documents

Publication Publication Date Title
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
LT3580220T (lt) Aminotriazolopiridinai, kaip kinazės inhibitoriai
IL269196A (en) Novel inhibitors
DK3303334T3 (da) Tyrosinkinasehæmmere
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MA42242A (fr) Inhibiteurs de la tyrosine kinase
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
BR112017025986A2 (pt) inibidores de tirosina quinase de bruton.
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
HUE050842T2 (hu) Janus-kináz inhibitor
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
LT3609898T (lt) Junginiai, naudingi kaip ret inhibitoriai
SI3145929T1 (sl) 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze
DK3290418T3 (da) Janus Kinase (JAK)-hæmmere
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
DK3592745T3 (da) Pyrimidopyrimidinoner anvendelige som Wee-1 kinaseinhibitorer
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3600301A4 (en) KDM4 INHIBITORS
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu